Oncology · Supportive CareRegulatory Approvalregulatorymid-term

FDA grants approval status for Leucovorin Calcium ANDA072736

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/3/2026, 12:33:06 PM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Hikma's ANDA072736 for Leucovorin Calcium is significant as it strengthens Hikma's position in the oncology supportive care market. This development may influence competitive dynamics and pricing strategies among generic manufacturers. Regulatory context from FDA (FDA AP — ROSUVASTATIN CALCIUM (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (10 high-relevance).

Strategic Assessment

The strongest clinical anchor is Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Supportive Care, 7 regulatory and 4 competitive items passed relevance filtering for Hikma. Hikma's approval could lead to increased market share and competitive pricing pressures in the oncology supportive care segment, impacting revenue for other players.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer. This approval status may enhance Hikma's competitive position in the oncology supportive care market, particularly against other generic manufacturers.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ROSUVASTATIN CALCIUM (SUPPL) (FDA). Regulatory pathway relevance (nda). The approval status indicates compliance with FDA standards, but the market entry timeline will be crucial for assessing its full impact on the competitive landscape.

Key Risks

Elevated medium regulatory exposure for Hikma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Hikma's approval could lead to increased market share and competitive pricing pressures in the oncology supportive care segment, impacting revenue for other players.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Upside for Hikma may improve if Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study. (PubMed) delivers favorable follow-through.
The implications of this approval on market share and pricing strategies for Leucovorin Calcium.

What Would Change This Assessment

This becomes more urgent if Monitor for further developments regarding the launch timeline and market entry of Hikma's Leucovorin Calcium.
Timeline shift beyond mid term would change urgency.
Outcome from Other | Cancer Accelerated Approvals would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Nutritional Care After Discharge in Children Term Born-18years Old
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Restraints in Intensive Care Unit Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Community Health Worker Based Intervention to Improve Palliative Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Point-of-Care Echocardiography in Patients With Known or Suspected Aortic Stenosis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of a brief primary care intervention for post-traumatic stress disorder symptoms after critical illness on health-related quality of life - A secondary analysis of the PICTURE randomised contr
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Bridging gaps in community cancer care: exploring Traditional Health Practitioners' perceptions of common adult cancer and their role in raising community awareness and early detection in Soweto, Sout
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Barriers to satisfactory primary care contacts for Swedish cancer survivors: a cross-sectional survey.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hikma
generic manufacturers

Commercial impact

medium

Hikma's approval could lead to increased market share and competitive pricing pressures in the oncology supportive care segment, impacting revenue for other players.

Regulatory impact

medium

The approval status indicates compliance with FDA standards, but the market entry timeline will be crucial for assessing its full impact on the competitive landscape.

What to watch

Monitor for further developments regarding the launch timeline and market entry of Hikma's Leucovorin Calcium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.